This “Checkpoint kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Checkpoint kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Checkpoint kinase inhibitors Understanding
Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. The checkpoint kinases, Chk1 and Chk2 are Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is repaired. The development of checkpoint kinase inhibitors for the treatment of cancer has been a major objective in drug discovery. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. The majority of CHK1 inhibitors are ATP competitive and bind directly to the hinge peptide region found between the N- and C-terminal lobes of the kinase domain. Checkpoint kinase inhibitors offer the promise of enhancing the effectiveness of widely prescribed cancer chemotherapies and radiotherapy by inhibiting the DNA damage response, as well as the potential for single agent efficacy. Due to their potential application as novel anticancer therapies, inhibitors of CHK1 and CHK2 have become the focus of numerous drug discovery projects.
Report Highlights
This segment of the Checkpoint kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Checkpoint kinase inhibitors Emerging Drugs
BI 765063: Boehringer Ingelheim
BI 765063 (OSE-172) is a monoclonal antibody, SIRPα an antagonist and first-in-class myeloid checkpoint inhibitor which selectively inhibits SIRPα thus restoring TAM and dendritic cells' activity in response to tumors. Boehringer Ingelheim is evaluating the potential drug in Phase 1 clinical trial in patients with advanced solid tumors.
CBP501: CanBas
CBP501 is a peptide mimetic for the treatment of solid tumors. CBP501 is a version of TAT-S216A optimized for its G2 checkpoint abrogating activity by using a cell cycle phenotype-based screening method, proprietary to CanBas. CBP501 enhance the inhibition of tumor growth by cisplatin, carboplatin, or bleomycin in vivo in a variety of mouse tumor xenograft models without significant adverse effects, but CBP501 also enhances the efficacy of several immune checkpoint inhibitors when these are used in combination with cisplatin or carboplatin. The drug is currently in Phase Ib clinical evaluation for the treatment of Advanced Refractory Tumors.
This segment of the report provides insights about the different Checkpoint kinase inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 15+ key companies which are developing the Checkpoint kinase inhibitors. The companies which have their Checkpoint kinase inhibitors drug candidates in the most advanced stage, i.e. Registration include, GlaxoSmithKline.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Checkpoint kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Checkpoint kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Checkpoint kinase inhibitors drugs.
Research program: anticancer therapeutics
Research program: checkpoint kinase inhibitors
Geography Covered
- Global coverage
Checkpoint kinase inhibitors Understanding
Checkpoint kinase inhibitors: Overview
Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. The checkpoint kinases, Chk1 and Chk2 are Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is repaired. The development of checkpoint kinase inhibitors for the treatment of cancer has been a major objective in drug discovery. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. The majority of CHK1 inhibitors are ATP competitive and bind directly to the hinge peptide region found between the N- and C-terminal lobes of the kinase domain. Checkpoint kinase inhibitors offer the promise of enhancing the effectiveness of widely prescribed cancer chemotherapies and radiotherapy by inhibiting the DNA damage response, as well as the potential for single agent efficacy. Due to their potential application as novel anticancer therapies, inhibitors of CHK1 and CHK2 have become the focus of numerous drug discovery projects.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint kinase inhibitors R&D. The therapies under development are focused on novel approaches for Checkpoint kinase inhibitors.
Checkpoint kinase inhibitors Emerging Drugs Chapters
This segment of the Checkpoint kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Checkpoint kinase inhibitors Emerging Drugs
BI 765063: Boehringer Ingelheim
BI 765063 (OSE-172) is a monoclonal antibody, SIRPα an antagonist and first-in-class myeloid checkpoint inhibitor which selectively inhibits SIRPα thus restoring TAM and dendritic cells' activity in response to tumors. Boehringer Ingelheim is evaluating the potential drug in Phase 1 clinical trial in patients with advanced solid tumors.
CBP501: CanBas
CBP501 is a peptide mimetic for the treatment of solid tumors. CBP501 is a version of TAT-S216A optimized for its G2 checkpoint abrogating activity by using a cell cycle phenotype-based screening method, proprietary to CanBas. CBP501 enhance the inhibition of tumor growth by cisplatin, carboplatin, or bleomycin in vivo in a variety of mouse tumor xenograft models without significant adverse effects, but CBP501 also enhances the efficacy of several immune checkpoint inhibitors when these are used in combination with cisplatin or carboplatin. The drug is currently in Phase Ib clinical evaluation for the treatment of Advanced Refractory Tumors.
Checkpoint kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Checkpoint kinase inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on Checkpoint kinase inhibitors
There are approx. 15+ key companies which are developing the Checkpoint kinase inhibitors. The companies which have their Checkpoint kinase inhibitors drug candidates in the most advanced stage, i.e. Registration include, GlaxoSmithKline.
Phases
This report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Checkpoint kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Checkpoint kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Checkpoint kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Checkpoint kinase inhibitors drugs.
Checkpoint kinase inhibitors Report Insights
- Checkpoint kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Checkpoint kinase inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Checkpoint kinase inhibitors drugs?
- How many Checkpoint kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Checkpoint kinase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Checkpoint kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Checkpoint kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Boehringer Ingelheim
- CanBas
- Vernalis
- Sierra Oncology
- Pharos I&BT Co
- Array BioPharma
- Eli Lilly and Company
- Sentinel Oncology
- BriaCell Therapeutics
- IMPACT Therapeutics
- Pink Biopharma
Key Products
- BI 765063
- CBP501
- VER-250840
- SRA737 Sierra Oncology
- PHI-101
- Prexasertib
- SOL 578
Research program: anticancer therapeutics
- IMP 10
Research program: checkpoint kinase inhibitors
Table of Contents
IntroductionExecutive Summary
Checkpoint kinase inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Checkpoint kinase inhibitors - Analytical Perspective
In-depth Commercial Assessment
- Checkpoint kinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Checkpoint kinase inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
SRA737: Sierra Oncology
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
CBP501: CanBas
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
VER-250840: Vernalis
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Checkpoint kinase inhibitors Key Companies
Checkpoint kinase inhibitors Key Products
Checkpoint kinase inhibitors- Unmet Needs
Checkpoint kinase inhibitors- Market Drivers and Barriers
Checkpoint kinase inhibitors- Future Perspectives and Conclusion
Checkpoint kinase inhibitors Analyst Views
Checkpoint kinase inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for Checkpoint kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Checkpoint kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Boehringer Ingelheim
- CanBas
- Vernalis
- Sierra Oncology
- Pharos I&BT Co
- Array BioPharma
- Eli Lilly and Company
- Sentinel Oncology
- BriaCell Therapeutics
- IMPACT Therapeutics
- Pink Biopharma
